Global Finance News
11 Nov 2026, 09:01
Alcon Falls 6.8% After Hours as Narrowed Outlook Overshadows Q3 Growth
Alcon (NYSE: ALC) shares fell about 6.8% in after-hours trading after the eye-care company reported third-quarter growth but narrowed parts of its 2026 outlook and highlighted continued competitive pressure in its implantables business.
Third-quarter sales rose 5% year over year to $2.72 billion, while diluted EPS increased 13% to $0.54. Core diluted EPS rose 15% to $0.91, and core operating margin improved to 21.8% from 20.2% a year earlier.
Growth was broad but uneven. Surgical sales increased 4%, with consumables up 6% and equipment and other revenue up 11%. However, implantables sales declined 2% to $422 million as U.S. competitive pressure weighed on intraocular lens sales, partially offset by strong PanOptix Pro demand and international growth. Vision Care revenue increased 6%, led by an 8% rise in ocular health sales.
Operating income increased 15% to $381 million, helped by manufacturing efficiencies and $58 million of tariff refunds. Core operating income rose 13% to $591 million.
The key investor concern appears to be the updated outlook. Alcon now expects constant-currency sales growth of about 6%, versus its previous 5%-7% range. Core operating margin expansion was narrowed to 100-150 basis points from 90-190 basis points, while core EPS growth was tightened to 12%-14% from 12%-15%.
Management also said competitive pressures remain in some areas and expects roughly $40 million of net tariff impact for the full year, with about two-thirds of a recent tariff refund being reinvested into the business.
The 6.8% after-hours decline therefore appears to reflect disappointment with the tighter earnings outlook and ongoing U.S. implantables pressure, despite solid Q3 sales growth, margin expansion and double-digit core EPS growth.
Alcon (NYSE: ALC) shares fell about 6.8% in after-hours trading after the eye-care company reported third-quarter growth but narrowed parts of its 2026 outlook and highlighted continued competitive pressure in its implantables business.
Third-quarter sales rose 5% year over year to $2.72 billion, while diluted EPS increased 13% to $0.54. Core diluted EPS rose 15% to $0.91, and core operating margin improved to 21.8% from 20.2% a year earlier.
Growth was broad but uneven. Surgical sales increased 4%, with consumables up 6% and equipment and other revenue up 11%. However, implantables sales declined 2% to $422 million as U.S. competitive pressure weighed on intraocular lens sales, partially offset by strong PanOptix Pro demand and international growth. Vision Care revenue increased 6%, led by an 8% rise in ocular health sales.
Operating income increased 15% to $381 million, helped by manufacturing efficiencies and $58 million of tariff refunds. Core operating income rose 13% to $591 million.
The key investor concern appears to be the updated outlook. Alcon now expects constant-currency sales growth of about 6%, versus its previous 5%-7% range. Core operating margin expansion was narrowed to 100-150 basis points from 90-190 basis points, while core EPS growth was tightened to 12%-14% from 12%-15%.
Management also said competitive pressures remain in some areas and expects roughly $40 million of net tariff impact for the full year, with about two-thirds of a recent tariff refund being reinvested into the business.
The 6.8% after-hours decline therefore appears to reflect disappointment with the tighter earnings outlook and ongoing U.S. implantables pressure, despite solid Q3 sales growth, margin expansion and double-digit core EPS growth.
